BTK and lymphoid leukemia: Notably, activation of BTK signaling is an essential feature of some B-cell malignancies such as chronic lymphoid leukemia (CLL) and Waldenstrom’s macroglobulinemia (WM), and inhibitors of BTK (i.e., ibrutinib) are standard of care therapies for these cancers.